What is the recommended initial management and treatment plan for hypertension in an adult?

Initial Management and Treatment of Hypertension in Adults

For adults with confirmed hypertension, begin with lifestyle modifications immediately and initiate pharmacological therapy with a thiazide/thiazide-like diuretic, ACE inhibitor, ARB, or long-acting calcium channel blocker as monotherapy for stage 1 hypertension, or as combination therapy (preferably single-pill combination) for stage 2 hypertension, targeting blood pressure <130/80 mmHg in most patients. 1, 2

Blood Pressure Targets

• Standard target: <140/90 mmHg for all patients 3, 4
• Intensive target: <130/80 mmHg for patients with:
  • Diabetes mellitus 5, 6
  • Chronic kidney disease 5, 4
  • High cardiovascular risk (≥7.5% 10-year risk) 1, 7
• Consider <120 mmHg systolic in selected high-risk patients (age ≥50 years with clinical CVD, chronic kidney disease, or 10-year CVD risk ≥15%) 4, 1

The 2025 AHA/ACC guidelines 1 and 2024 ESC guidelines 2 represent the most current evidence, both advocating for lower targets than older guidelines. The shift toward <130/80 mmHg is supported by trials like SPRINT showing reduced cardiovascular events and mortality with intensive control 8, 7.

Lifestyle Modifications (Apply to ALL Patients)

Implement these evidence-based interventions before or concurrent with pharmacotherapy:

• Sodium restriction: <2000 mg (87 mmol) per day 4
• DASH diet: Emphasize fruits, vegetables, low-fat dairy, whole grains, plant protein; reduce saturated fat 3, 9, 4
• Physical activity: 30-60 minutes of moderate aerobic exercise 4-7 days/week 3, 9
• Weight management: Target BMI 18.5-24.9 kg/m², waist <102 cm (men) or <88 cm (women) 3, 9
• Alcohol limitation: ≤14 drinks/week (men) or ≤9 drinks/week (women) 3, 9
• Potassium supplementation: Increase dietary potassium if not at risk for hyperkalemia 4

Pharmacological Treatment Strategy

Initial Drug Selection

For uncomplicated hypertension (no compelling indications):

First-line options include 3, 4, 1, 2:

• Thiazide/thiazide-like diuretics (chlorthalidone or indapamide preferred over hydrochlorothiazide) 8
• ACE inhibitors (avoid as monotherapy in Black patients) 3, 9
• Angiotensin receptor blockers (ARBs)
• Long-acting calcium channel blockers (dihydropyridine type)
• Beta-blockers (only in patients <60 years old) 9, 10, 4

Critical caveat: Beta-blockers are NOT recommended as first-line therapy in patients ≥60 years with uncomplicated hypertension 9, 10. Alpha-blockers are NOT first-line agents 9.

Monotherapy vs. Combination Therapy

Stage 1 hypertension (SBP 130-139 or DBP 80-89 mmHg):

• Start with monotherapy 1, 2
• Use stepped-care approach: titrate dose, then add second agent if needed

Stage 2 hypertension (SBP ≥140 or DBP ≥90 mmHg):

• Initiate combination therapy with 2 first-line agents if SBP is ≥20 mmHg above target or DBP is ≥10 mmHg above target 5, 3, 4, 1
• Single-pill combinations are strongly preferred over separate pills to improve adherence and reduce cardiovascular events 1, 2
• Exercise caution in elderly/frail patients who may not tolerate rapid BP reduction 5, 9

Recommended combinations 4, 2:

• ACE inhibitor + calcium channel blocker
• ARB + calcium channel blocker
• ARB + thiazide diuretic
• ACE inhibitor + thiazide diuretic

NEVER combine: ACE inhibitor + ARB (increases adverse events without benefit) 5, 3, 1, 2

Treatment Intensification

If BP remains uncontrolled on dual therapy:

1. Add a third agent from a different class (typically completing the RAS blocker + CCB + diuretic triple combination) 2
2. Ensure medication adherence before escalating therapy 2

Resistant Hypertension (BP ≥130/80 on ≥3 drugs including a diuretic)

After confirming adherence and excluding white coat effect:

1. Add spironolactone (25-50 mg daily) as fourth-line agent 4, 2
2. If spironolactone not tolerated: consider eplerenone, other mineralocorticoid receptor antagonists, or beta-blockers 2
3. Screen for primary aldosteronism in all patients with resistant hypertension 8, 1
4. Refer to hypertension specialist 2

Special Populations

Diabetes Mellitus

• Target: <130/80 mmHg 5, 6
• Preferred agents: ACE inhibitors or ARBs (especially if albuminuria present) 5, 6
• If no albuminuria: any first-line agent acceptable, but prioritize ACE inhibitor/ARB for renal protection 5

Chronic Kidney Disease

• Target: <130/80 mmHg 3, 4
• Initial therapy: ACE inhibitor or ARB (if proteinuria >500 mg/24h or ACR >30 mg/mmol) 5
• Add thiazide diuretic; use loop diuretic if volume overload present 5
• Do NOT combine ACE inhibitor + ARB in non-proteinuric CKD 5

Isolated Systolic Hypertension

• Preferred agents: Thiazide diuretics, long-acting dihydropyridine CCBs, or ARBs 3, 9

Black Patients

• Preferred initial therapy: Calcium channel blocker or thiazide diuretic 3, 11
• ACE inhibitors less effective as monotherapy but appropriate in combination or with compelling indications 9

Monitoring and Follow-Up

• Initial phase: Monthly visits until BP target achieved 8
• Once controlled: Extend to 90-day follow-up intervals 8
• Home BP monitoring strongly recommended for medication titration and detecting white coat/masked hypertension 8, 4
• Ambulatory BP monitoring if office BP ≥140/90 mmHg to confirm diagnosis 3, 12

Common Pitfalls to Avoid

1. Clinical inertia: Failure to intensify therapy when BP remains above target is the most common reason for poor control 8
2. Inadequate dosing: Use maximum tolerated doses before adding additional agents
3. Poor adherence: Address with once-daily dosing, single-pill combinations, and medication reminder systems 1
4. Ignoring out-of-office BP: Office readings alone miss white coat and masked hypertension 3, 8
5. Combining ACE inhibitor + ARB: This increases harm without benefit 5, 3, 1
6. Using beta-blockers in elderly: Not recommended as first-line in patients ≥60 years 9, 10

The evidence strongly supports early, aggressive treatment to prevent cardiovascular morbidity and mortality, with most patients requiring 2-3 medications to achieve target BP 3, 6, 2.